International journal of pharmaceutical compounding · 2019
Compounding for Patients with Polycystic Ovarian Syndrome (Stein-Leventhal Syndrome).
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Riepl Mike
Аннотация
Polycystic ovary syndrome (Stein- Leventhal syndrome) is a common endocrinopathologic condition in reproductive- age women in the U.S. Patients with that disease are not faced with treatment choices for a single medical entity; they must manage a constellation of comorbid conditions that compromise their overall health and diminish their quality of life. The combinations of those disorders are unique to each patient. As a result, the safest and most effective therapeutic approach often requires precision pharmacy: the use of compounded therapies that, unlike commercially manufactured medications, can be precisely adjusted to meet individual needs and modified as therapeutic requirements change. In this article, the manifestations of polycystic ovary syndrome are reviewed, several common concomitant conditions are discussed, therapeutic interventions are suggested, and compounded formulations are provided.